United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 mg per kg per day or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated popu

United States - English - NLM (National Library of Medicine)

lohxa - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 mg per kg per day or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimate

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 mg per kg per day or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated popu

United States - English - NLM (National Library of Medicine)

a-s medication solutions - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology ( 12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the est

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: and . s. aureus s. pyogenes this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment usp, 2% is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp, 2%. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [ see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects

United States - English - NLM (National Library of Medicine)

unit dose services - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus  aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the es

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment usp, 2% is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp, 2%. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated popula

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment usp, 2% is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp, 2%. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [ see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects